UChicago Annual Updates from ASH 2019
Avatar

ASH 2019 Updates on Treatment of Young 'Fit' CLL Pts: Improved PFS and OS With Ibrutinib + Rituximab & iFCG Regimen Effective for Pts With IGHV Mutations

By UChicago Annual Updates from ASH 2019 FEATURING Nitin Jain
By UChicago Annual Updates from ASH 2019 FEATURING Nitin Jain
719 views
March 20, 2020
0 Comments
Login to view comments. Click here to Login

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay

Related Content

AUTOPLAY
21:05
Louisville Hematology Highlights

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Feat. R. Gale
12:47
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Summary: "Experts Discuss Key Abstracts in CLL"

Feat. S. O'Brien, C. Coombs
17:05
Cleveland Clinic Taussig Cancer Institute

Frontline CLL Learnings From Phase 3 RESONATE-2, iLLUMINATE, and E19…

Feat. A. Winter
50:34
Scripps MD Anderson Cancer Center

The Cure of Leukemias in the Next Decade: An Optimist’s View

Feat. H. Kantarjian
06:53
UC Irvine Health

Fixed-Duration Treatment in CLL: Current Considerations

Feat. E. Brem
24:33
Indy Hematology Review

Therapeutic Options in CLL in 2023: Choosing the Initial Therapy Wis…

Feat. J. Woyach
08:17
Adam Kittai

Highlights From iwCLL 2023: What's New and Practice Informing i…

10:06
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Results of A041702, an Alliance Phase 3 S…

Feat. J. Woyach
15:21
5th SOHO Italy Annual Conference

SOHO Italy 2023: How I Treat CLL at the MD Anderson Cancer Center

Feat. A. Ferrajoli
06:28
Insights from 2023 EHA® Annual Meeting

EHA® 2023 Insights: "Venetoclax + Obinutuzumab for Previously U…

Feat. O. Al-Sawaf
06:21
City of Hope

Cardiac Safety of Zanubrutinib vs. Other BTKis in CLL

Feat. A. Danilov
11:39
5th SOHO Italy Annual Conference

SOHO Italy 2023: Current Approach to Sequencing CLL Therapy in the R…

Feat. G. Gaidano
18:01
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "MRD-Directed Therapy in CLL - Ready for Pri…

Feat. J. Rhodes
13:16
ASH 2022 Conference Coverage

Experts Discuss Key Updates in CLL

Feat. S. O'Brien, C. Coombs
17:21
Daniel Addison

Cardiovascular Considerations With (Contemporary) BTKi in the Treatm…

10:22
SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Next Questions: CLL

Feat. N. Jain
09:27
RWJBarnabas Health Rutgers Cancer Institute of New Jersey

Fixed Duration Treatment in CLL

Feat. J. Kra
28:43
Scripps MD Anderson Cancer Center Clinical Hematology & Oncology 2023

Scripps MD Anderson Cancer Center Updates on CLL/SLL Frontline Thera…

Feat. S. O'Brien
10:35
Alan Skarbnik

Learnings From the ELEVATE-TN Phase 3 Trial: Acalabrutinib+/-Obinutu…

16:16
Insights from 2023 EHA® Annual Meeting

Experts Discuss Key Updates in CLL From EHA and iCML

Feat. S. O'Brien, C. Coombs